Neuronity Therapeutics Secures $780k Grant from The Michael J. Fox Foundation for Parkinson's Research
BOSTON - July 3, 2023 - PRLog -- Neuronity Therapeutics, Inc., a pioneering biotech company focused on neurodegenerative diseases, is delighted to announce the receipt of a $780k grant in collaboration with the University of Georgia (UGA) from The Michael J. Fox Foundation (MJFF). As the largest nonprofit foundation for Parkinson's disease, MJFF's Therapeutics Pipeline Program (TPP) aims to accelerate the development of therapeutic pipelines in partnership with academia and industry.
Neuronity has forged a collaboration with Dr. Jae-Kyung Lee, Associate Professor of Physiology and Pharmacology, at UGA to advance a research program aimed at restoring homeostasis of microglia, the residential immune cells in the brain affected by Parkinson's disease. This groundbreaking 18-month project will support Neuronity and UGA in validating a clinically applicable gene therapy utilizing Adeno-Associated Virus to upregulate target molecules in microglia. The innovative gene therapy holds a substantial potential to modify disease outcomes for Parkinson's disease patients.
"The grant from MJFF is a significant milestone for Neuronity in our therapeutic development journey, as well as an acknowledgment of the support from the esteemed shareholders in MJFF's community," expressed Hyun Joon Lee, PhD, Founder and CEO of Neuronity. "We are thrilled to have the opportunity to engage with these shareholders and collaborate with MJFF's staff for our upcoming fundraising efforts. The collaboration with Dr. Jae-Kyung Lee will ensure that we maintain a high standard of scientific research while progressing towards the clinical development of this therapy."
Through this grant, Neuronity will not only receive vital financial support but will also gain access to MJFF's extensive network of researchers and advisors, both within their community and among external partners. This invaluable network will provide valuable guidance and foster collaboration, further propelling Neuronity's mission to develop effective treatments for Parkinson's disease.
Neuronity is committed to making a positive impact on the lives of Parkinson's disease patients, and this grant from MJFF reaffirms their dedication to advancing innovative therapies. The company looks forward to the next phase of their research and development journey, working closely with MJFF, UGA, and their shareholders to bring about meaningful change in the field of neurodegenerative diseases.
About Neuronity Therapeutics, Inc.: Neuronity is a biotech company dedicated to revolutionizing the treatment of neurodegenerative diseases. With a focus on age-related neurological disorders, such as Parkinson's disease, our cutting-edge gene and cell therapy programs aim to restore healthy immune cell function in aging brains. By targeting the root causes of these conditions, we strive to reduce the unmet needs of patients, families, and caregivers. Our mission is to improve the quality of life for individuals affected by neurodegenerative diseases through groundbreaking interventions and strategic collaborations. Neuronity accomplished the prestigious Fall 2022 Science Inc.™ Accelerator Program, hosted by the Innovation Space in Delaware and formed a team of exceptional scientists and enlisted the support of seasoned advisors. For more information, visit: www.neuronitytx.com or find us on LinkedIn at Neuronity Therapeutics, Inc.
Hyun Joon Lee, PhD